Doxorubicin (Dox) is a secondary metabolite of the mutated strain of Streptomyces peucetius
var. Caesius and belongs to the anthracyclines family. The anti-cancer activity of Dox is …

Doxorubicin is an effective chemotherapeutic agent prescribed to treat solid tumors (eg,
ovary, breast, and gastrointestinal cancers). This anti-cancer drug has various side effects …

Doxorubicin (DOX), a chemotherapeutic agent, induces a cardiotoxicity referred to as
doxorubicin-induced cardiomyopathy (DIC). This cardiotoxicity often limits chemotherapy for …

Oxidative stress and cardiomyocyte apoptosis play critical roles in doxorubicin (DOX)-
induced cardiotoxicity. Previous studies indicated that fibronectin type III domain-containing …

Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which
is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although …

Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

Background Doxorubicin, an anthracycline chemotherapeutic agent, is widely used in the
treatment of many cancers. However, doxorubicin posts a great risk of adverse …

Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and
cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have …

Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy
protocols. Severe side effects such as cardiotoxicity, however, limit Dox application …

Doxorubicin (DOX) is a highly effective anticancer anthracycline drug, but its side effects at
the level of the heart has limited its widespread clinical application. Melatonin is a …